ZIM Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
ZIM Laboratories has a total shareholder equity of ₹2.4B and total debt of ₹973.5M, which brings its debt-to-equity ratio to 40.1%. Its total assets and total liabilities are ₹4.3B and ₹1.8B respectively. ZIM Laboratories's EBIT is ₹272.5M making its interest coverage ratio 3.2. It has cash and short-term investments of ₹58.1M.
Key information
40.1%
Debt to equity ratio
₹973.53m
Debt
| Interest coverage ratio | 3.2x |
| Cash | ₹58.15m |
| Equity | ₹2.43b |
| Total liabilities | ₹1.85b |
| Total assets | ₹4.27b |
Recent financial health updates
Recent updates
ZIM Laboratories (NSE:ZIMLAB) Has A Somewhat Strained Balance Sheet
Nov 14
ZIM Laboratories' (NSE:ZIMLAB) Anemic Earnings Might Be Worse Than You Think
May 21Earnings Not Telling The Story For ZIM Laboratories Limited (NSE:ZIMLAB) After Shares Rise 28%
Apr 26ZIM Laboratories Limited's (NSE:ZIMLAB) Shares May Have Run Too Fast Too Soon
Feb 20Estimating The Fair Value Of ZIM Laboratories Limited (NSE:ZIMLAB)
May 16Sentiment Still Eluding ZIM Laboratories Limited (NSE:ZIMLAB)
Nov 29Financial Position Analysis
Short Term Liabilities: ZIMLAB's short term assets (₹1.9B) exceed its short term liabilities (₹1.3B).
Long Term Liabilities: ZIMLAB's short term assets (₹1.9B) exceed its long term liabilities (₹540.4M).
Debt to Equity History and Analysis
Debt Level: ZIMLAB's net debt to equity ratio (37.7%) is considered satisfactory.
Reducing Debt: ZIMLAB's debt to equity ratio has reduced from 51.8% to 40.1% over the past 5 years.
Debt Coverage: ZIMLAB's debt is well covered by operating cash flow (30.7%).
Interest Coverage: ZIMLAB's interest payments on its debt are well covered by EBIT (3.2x coverage).